Gilead Sciences (NASDAQ:GILD) reports earnings on July 23. According to Bloomberg, analysts are estimating over $2.8 billion in sales. But remember that analysts were off -- off by a lot! -- last quarter in guessing sales, with Gilead's $2.3 billion in Sovaldi sales crushing their expectations. Could Gilead surprise to the upside again? Watch the video below for our take.
Deputy Managing Editor, Fool.com. I started in Healthcare, and that will always be my first love. You'll find me writing regularly about biotech, dividend stocks, and personal finance.
- Jul 21, 2014 at 5:00PM
- Health Care